Treatment of COVID-19 patients with a SARS-CoV-2-specific siRNA-peptide dendrimer formulation. Musa Khaitov , Alexandra Nikonova , Ilya Kofiadi , Igor Shilovskiy , Valeriy Smirnov , Olga Elisytina , Artem Maerle , Artem Shatilov , Anastasia Shatilova , Sergey Andreev , Ilya Sergeev , Dmitry Trofimov , Tatyana Latysheva , Natalia Ilyna , Alexander Martynov , Sevastyan Rabdano , Ellina Ruzanova , Nikita Savelev , Iuliia Pletiukhina , Ariana Safi , Vyacheslav Ratnikov , Viktor Gorelov , Viktor Kaschenko , Natalya Kucherenko , Irina Umarova , Svetlana Moskaleva , Sergei Fabrichnikov , Oleg Zuev , Nikolai Pavlov , Daria Kruchko , Igor Berzin , Dmitriy Goryachev , Vadim Merkulov , German Shipulin , Sergey Udin , Victor Trukhin , Rudolf Valenta , Veronica Skvortsova Allergy（2023）
摘要
siR-7-EM/KK-46, a SARS-CoV-2-specific siRNA-peptide dendrimer formulation is safe, well tolerated and significantly reduces time to clinical improvement in patients hospitalized with moderate COVID-19 compared to standard therapy in a randomized controlled trial.
更多 查看译文
关键词
SARS-CoV-2, clinical trial, efficacy, safety, siRNA
AI 理解论文
溯源树
样例
